Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,616.50
Bid: 1,618.00
Ask: 1,618.50
Change: 4.50 (0.28%)
Spread: 0.50 (0.031%)
Open: 1,607.50
High: 1,620.00
Low: 1,594.00
Prev. Close: 1,612.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Britain to spend $5 billion on vaccines and bear liability, watchdog says

Wed, 16th Dec 2020 00:01

LONDON, Dec 16 (Reuters) - Britain has agreed to spend 3.7
billion pounds ($4.93 billion) on COVID-19 vaccines and in most
cases will bear the liability if claims are made against the
pharmaceutical firms involved, the National Audit Office (NAO)
said on Wednesday.

The government has agreed supply deals for 357 million doses
of seven different candidate shots, but has not gone into detail
about how much it has spent or indemnity agreements, citing
commercial confidentiality around the contracts.

The NAO said the business ministry had signed firm deals for
five of the candidates, including the Pfizer/BioNTech shot which
has already been approved and is being rolled out, as well as
those developed by Oxford/AstraZeneca, France's Valneva, Novavax
and Moderna.

Britain also has deals in principle for
Sanofi/GlaxoSmithKline's shot as well as Johnson & Johnson's
candidate.

The government has invested in the development and clinical
trials of some of the vaccines it has agreed supply deals for,
and agreed to indemnify the firms against liability.

Those agreements mean that in four of the five finalised
contracts, there was no cap on how much the government could pay
if there is a successful claim against one of the companies, the
report said.

The NAO said the business ministry agreed upfront payments
of 914 million pounds on the five contracts it has signed, prior
to regulatory approval of any of the vaccines.

Only one of the contracts provides for a full refund of the
upfront payment if the vaccine fails to achieve regulatory
approval.

The NAO noted that the government had worked "quickly and
effectively" to secure vaccines, demonstrated when Britain
became the first country in the world to deploy Pfizer's
vaccine last week.

"We have worked at a pace and scale never been done before
to ensure the British public receive a vaccine that meets strict
safety standards as quickly as possible," a spokeswoman for the
business ministry said.

In all, the total cost of purchasing and deploying vaccines
was uncertain, the NAO said, but estimated that it could cost up
to 11.7 billion pounds.

($1 = 0.7505 pounds)
(Reporting by Alistair Smout; Editing by Tom Brown)

More News
12 Feb 2024 12:04

LONDON MARKET MIDDAY: FTSE 100 underperforms as European peers rise

(Alliance News) - London's FTSE 100 underwhelmed on Monday, with some of its largest constituents pulling it lower, while indices in Europe were on the up on favourable comments on interest rate cuts by a European Central Bank official.

Read more
12 Feb 2024 08:35

TOP NEWS: GSK's bepirovirsen receives US FDA fast track designation

(Alliance News) - GSK PLC on Monday said that the US health watchdog granted fast track designation for its bepirovirsen treatment for chronic hepatitis B.

Read more
12 Feb 2024 07:50

LONDON BRIEFING: Tritax Big Box, UK Commercial Property agree merger

(Alliance News) - Equities in London are called to open higher on Monday, with inflation readings from the US and UK on the horizon, which could drive equity market sentiment during the remainder of the week.

Read more
12 Feb 2024 07:21

GSK gets FDA fast track for chronic hepatitis B treatment

(Sharecast News) - GSK announced on Monday that bepirovirsen, an investigational antisense oligonucleotide (ASO) aimed at treating chronic hepatitis B (CHB), had been granted fast track designation by the US Food and Drug Administration (FDA).

Read more
9 Feb 2024 09:15

LONDON BROKER RATINGS: Deutsche Bank cuts AstraZeneca to 'sell'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
6 Feb 2024 08:51

TOP NEWS: GSK reports positive news on trio of high profile products

(Alliance News) - GSK PLC on Tuesday delivered a triple dose of positive updates on some of its leading products, Arexvy, Shingrix and Blencep.

Read more
6 Feb 2024 07:47

LONDON BRIEFING: BP promises buyback despite drop in profit

(Alliance News) - Stocks in London are called to open higher, ahead of a slew of construction purchasing managers' index readings from the eurozone, the UK and Germany.

Read more
6 Feb 2024 07:23

GSK reports positive myeloma trial results, progresses vaccine applications

(Sharecast News) - GSK reported progress in its trial of a myeloma treatment on Tuesday, as well as regulatory progress around its shingles vaccine in China and its RSV vaccine in the United States.

Read more
1 Feb 2024 09:27

TOP NEWS: GSK maintains "vigorous" defence after settling Zantac case

(Alliance News) - GSK PLC on Thursday insisted upon its scientific integrity, after reaching another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
1 Feb 2024 09:11

GSK settles Zantac case in California without admitting liability

(Sharecast News) - GSK announced on Thursday that it had reached a confidential settlement to effectively resolve the legal case over Zantac filed in a California state court.

Read more
1 Feb 2024 09:03

LONDON BROKER RATINGS: Barclays cuts Next; JPMorgan raises easyJet

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
1 Feb 2024 07:42

LONDON BRIEFING: Shell profit falls; announces USD3.5 billion buyback

(Alliance News) - Stocks in London are set to follow New York into the red, after the US Federal Reserve quashed hopes of a March cut to interest rates and ahead of the Bank of England interest rate decision.

Read more
31 Jan 2024 17:05

LONDON MARKET CLOSE: Stocks mixed hours before expected US Fed hold

(Alliance News) - Stock prices in London closed mixed on Wednesday in a trade-thinned day ahead of the US Federal Reserve interest rate decision this evening.

Read more
31 Jan 2024 15:49

London close: Stocks mixed ahead of US Fed, BoE decisions

(Sharecast News) - London's financial markets finished with mixed performance on Wednesday, with investors closing their wallets ahead of rate announcements from both the US Federal Reserve and the Bank of England.

Read more
31 Jan 2024 12:05

LONDON MARKET MIDDAY: FTSE 100 flat ahead of Federal Reserve decision

(Alliance News) - The FTSE 100 in London was flat heading into Wednesday afternoon, as the US Federal Reserve's latest interest rate decision edges closer, keeping equity market enthusiasm to a minimum.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.